4basebio PLC (LON:4BB) Insider Acquires £28,920 in Stock

4basebio PLC (LON:4BB) insider Heikki Lanckriet purchased 2,400 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The shares were purchased at an average cost of GBX 1,205 ($15.53) per share, for a total transaction of £28,920 ($37,277.65).

4basebio Price Performance

LON 4BB opened at GBX 1,205 ($15.53) on Monday. The company has a market cap of £154.36 million, a PE ratio of -1,544.87 and a beta of 1.09. The firm’s 50 day moving average price is GBX 1,142.07 and its 200-day moving average price is GBX 1,229.09. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73. 4basebio PLC has a 52-week low of GBX 901 ($11.61) and a 52-week high of GBX 1,820 ($23.46).

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and issued a GBX 1,600 ($20.62) price objective on shares of 4basebio in a research note on Thursday, March 13th.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.